Photo of Paolo Tarantino from X
Nov 6, 2023, 04:03
Paolo Tarantino: Make sure not to miss our presentation of RELIEVE at the San Antonio Breast Cancer Symposium (SABCS23)
Paolo Tarantino, Research Fellow at the Dana-Farber Cancer Institute, shared on X/Twitter:
“Trastuzumab Deruxtecan (T-DXd) outperformed chemo for the treatment of HER2-low Metastatic Breast Cancer (MBC). But how does it perform among patients with dynamic changes in HER2 status? Does it also work if the most recent biopsy was HER2-0? Make sure not to miss our presentation of RELIEVE at the San Antonio Breast Cancer Symposium (SABCS23)!”
Source: Paolo Tarantino/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19
Dec 21, 2024, 19:18